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Lorcainide in Patients With Refractory Ventricular Tachyarrhythmia
BRIAN CHESNIE, MD, STEVEN LAMPERT, MD, PHILIP PODRID, MD, FACC,
BERNARD LOWN, MD, FACC
Boston, Massachusetts
Lorcainide, a new antiarrhythmic agent with local an-
esthetic or membrane-stabilizing properties similar to
those of quinidine, was tested in 76 patients with diverse
types of heart disease and recurrent ventricular tachy-
cardia or ventricular fibrillation. Lorcainide was ad-
ministered for 72 to 96 hours in a dose ranging from
200 to 400 mg daily. Evaluation of drug efficacy involved
ambulatory monitoring and exercise stress testing in 60
patients who had high grade ventricular arrhythmia.
Invasive electrophysiologic testing was carried out in the
remaining 16 patients who exhibited infrequent ventric-
ular ectopic activity during control studies. Lorcainide
was effective in 21 (38%) of 56 patients evaluated for
suppression of ventricular ectopic activity and in 6 (40%)
of 15 who had invasive testing. In five patients, the drug
Treatment of ventricular arrhythmias is hindered by a scarc-
ity of safe and effective drugs. This constitutes a pressing
clinical problem as increasing numbers of patients are being
recognized who demonstrate advanced grades of ventricular
ectopic activity that may augur sudden cardiac death (1-3).
Furthermore, more patients are surviving with advanced
degrees of myocardial impairment who suffer from fre-
quently recurring episodes of life-threatening arrhythmias
(4,5). Quinidine, procainamide, disopyramide, diphenylhy-
dantoin, digitalis glycosides, bretylium tosylate and diverse
beta-adrenergic blocking drugs currently constitute the
available antiarrhythmic armamentarium for such disorders.
These drugs frequently either are ineffective or result in
unacceptable side effects. There is, therefore, need to resort
to newer and as yet experimental agents. One such agent
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was discontinued because of toxic reactions. Thus, 27
(38%) of the 71 patients who completed the drug study
responded to lorcainide.
Side effects, reported by 42 patients (55.3%), con-
sisted primarily of insomnia and gastrointestinal symp-
toms; 7 experienced aggravation of arrhythmia. Fifteen
patients were discharged while receiving lorcainide ther-
apy, but in four the treatment was discontinued after 2
months because of side effects. Three patients died, one
suddenly.
It is concluded that lorcainide is of value in a small
subset of patients with life-threatening ventricular ar-
rhythmias who have proven refractory to conventional
drugs. Its usefulness is limited by the high frequency of
insomnia.
under active investigation, lorcainide, is a potent local an-
esthetic with membrane-stabilizing activity. It has been re-
ported to suppress a number of experimentally induced ar-
rhythmias in animal models (6). Although there are clinical
studies of the drug in human beings (7,8), experience is as
yet limited. This report presents results of lorcainide therapy
in a group of patients who experienced recurrent episodes
of ventricular fibrillation or symptomatic ventricular
tachycardia.
Methods
Study patients. The study group consisted of 76 pa-
tients, 61 men and 15 women, with an average age of 53.4
years (range 16 to 71) (Table I). Forty-eight patients had
coronary heart disease, including 36 with a prior myocardial
infarction, 12 with cardiomyopathy, 8 with valvular disease
and 8 with no structural heart disease demonstrated by echo-
cardiography and cardiac catheterization. Thirty-four pa-
tients (44.7%) were receiving fixed dose digoxin therapy
for stable congestive heart failure.
All patients in this study had experienced recurrent, po-
tentially malignant ventricular arrhythmias (Table I). Of
these, 17 had ventricular fibrillation, and 59 had ventricular
tachycardia. In 26 patients, tachycardia was sustained, ac-
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Table 1. Study Patients
companied by syncope and required cardioversion; in 17 it
was sustained, symptomatic without syncope but with hy-
potension and required drug therapy or cardioversion. The
remaining 16 patients had salvos of ventricular tachycardia
lasting from 10 or more seconds to minutes and associated
with dizziness. In no case was the arrhythmia the result of
acute myocardial infarction or other identifiable provoking
factors.
Previous therapy with conventional agents (procainam-
ide, quinidine, propranolol and disopyramide) either had
failed or had caused serious side effects. A drug was deemed
ineffective if documented arrhythmia recurred at a time when
blood levels were greater than the established minimal ther-
apeutic level.
Study protocol. Control phase. The study consisted of
a control phase followed by a drug treatment period (9).
The control phase comprised a baseline evaluation period
to establish the frequency and type of ventricular arrhyth-
mia. All antIarrhythmic drugs were discontinued for four
half-lives, generally 36 to 48 hours. Immediately after the
washout period, patients underwent 48 hours of ambulatory
monitoring with a cassette tape recording system and max-
imal exercise tolerance testing on a motorized treadmill,
adhering to a Bruce protocol (10). The procedures for mon-
itoring and exercise testing have been previously described
(1,2,9).
Arrhythmia was categorized by the Lown grading system
(JJ): Grade 0 = no ventricular premature complexes; grade
IA = less than 30 ventricular premature complexes/h and
less than lImin; grade 1B = less than 30 ventricular pre-
mature complexes/h and occasionally more than lImin; grade
2 = greater than 30 ventricular premature complexes/h;
grade 3 = multiform ventricular premature complexes; grade
Table 2. Results of Control Studies in Patients Undergoing
Noninvasive Evaluation
*Two patients did not have grade 4B arrhythmia on a control monitor.
Figures in parentheses represent values per hour (monitoring) or per test
(exercise) .
24
34
10
II
39
53
48
14
46
46
No. of
Patients
No. of
Patients
Exercise Testing (n = 53)
Electrocardiographic
Monitoring (n = 60)
(% hours present)
Grade 2
50-74
75-99
100
Grade 4A
30-50
>50
(25 episodes)
Grade 4B*
25-50
>50
(14 salvos)
Grade 2
(178 ventricular premature complexes)
Grade 4A
(28 episodes)
Grade 4B
(9.4 salvos)
4A = repetItIve forms, couplets; grade 4B = repetItIve
forms, ventricular tachycardia; and grade 5 = early cycle
ventricular premature complexes (R on T phenomenon).
Noninvasive antiarrhythmic drug evaluation was per-
formed in the 60 patients who had grade 4A and 4B ar-
rhythmia exposed on monitoring or exercise stress testing
(grade 4B had to be present for at least 3 hours during each
24 hour period and grade 4A for at least 30% of the mon-
itored hours). Grade 2 arrhythmia was present in all 60
patients for at least 50% of the hours monitored and in 50
patients for more than 75% of the hours monitored (Table
2). The average number of hours of grade 2 arrhythmia was
19.8 per each monitoring period of 24 hours. Grade 4A
arrhythmia (couplets) was present in all 60 patients during
an average of 16.7 hours/day. The average couplet fre-
quency was 25/h. Salvos of ventricular tachycardia were
present in 58 patients during an average of 9.9 h124 h period
of monitoring. There was an average of 14 salvos/h with a
mean of 5.5 cycles (range 3 to 82) at a rate of 164 beats/min
(range 120 to 228).
During exercise, criteria for noninvasive evaluation were
the presence of an average of at least 2 ventricular premature
complexes/min during the entire exercise test and the oc-
currence of grade 4A and 4B ventricular arrhythmia. Fifty-
three patients underwent a control exercise tolerance test.
Seven patients did not undergo control exercise because of
76
61
15
48
12
8
8
34
17
59
26
17
16
No. of
Patients
53.4
16-71
Total
Men
Women
Age (yr)
Mean
Range
Heart disease
Coronary artery
Cardiomyopathy
Valvular
Not demonstrable
Congestive heart failure
Presenting arrhythmia
Ventricular fibrillation
Ventricular tachycardia
Sustained with syncope
Sustained with hypotension
Nonsustained salvos
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frequent episodes of sustained ventricular tachycardia re-
quiring constant monitoring and continuous intravenous in-
fusion of lidocaine. The mean (± standard deviation) ex-
ercise duration in the 53 patients was 6.3 ± 3.3 minutes.
Mean peak heart rate achieved was 148.8 ± 23.1 beats/min
and mean peak blood pressure was 144.2/76.5 ± 29.2112.3
mm Hg. Forty-six patients had salvos of ventricular tachy-
cardia during the exercise test. There were an average of
9.4 episodes/test, with an average of 14 beats per salvo at
an average heart rate of 174 ± 43 beats/min. Frequent
couplets were provoked in 48 patients with an average fre-
quency of 28/test. All patients had frequent ventricular pre-
mature complexes provoked by exercise with a mean of
178/test (Table 2). Thus, the maximal grade of arrhythmia
was 4B in 46 patients, 4A in 4 patients and grade 2 in 3
patients.
Drug evaluation by means of electrophysiologic testing
(12,13) was performed in patients who did not meet these
criteria. Under fluoroscopic guidance, a 6 French hexapolar
electrode catheter was inserted percutaneously into the left
subclavian vein and positioned at the right ventricular apex.
Programmed premature stimulation was performed, using
as many as three successive extrastimuli with a pulse width
of 5 ms at energies of two and three times mid-diastolic
threshold as previously reported (13). Studies were carried
out during both sinus rhythm and ventricular pacing at a
cycle length of 500 ms. The end point of stimulation was
the induction of reproducible nonsustained ventricular
tachycardia, defined as three or more ventricular tXtopic
beats (lasting up to 30 seconds) following the last provoked
extrastimulus (13). To be considered reproducible, the end
76 Patients
Noninvasive
point had to be provoked in two of three attempts at the
same coupling cycle and with the same stimulus energy.
Sixteen patients who had insufficient ventricular arrhythmia
underwent invasive electrophysiologic testing (Fig. I). In
seven patients, sustained ventricular tachycardia (lasting> 30
seconds) was provoked (Fig. 2). The average cycle length
of the tachycardia was 303 ms or a rate of 198 beats/min
(range 160 to 260). In all cases, the induced tachycardia
was of similar configuration to that which occurred clini-
cally. Overdrive with ventricular burst pacing terminated
the tachycardia in five patients, while lidocaine was effective
in two. In nine patients, nonsustained ventricular tachy-
cardia was induced. The average number of cycles was 9
(range 4 to 19) with a cycle length of 262 ms or a rate of
230 beats/min.
Lorcainide therapy. After control studies, lorcainide
therapy was begun at a dose of 100 mg twice daily and
increased after the first 36 hours to 150 mg or 200 mg twice
daily. Oxazepam or flurazepam have been reported to be
effective treatment for drug-related insomnia (8) and they
were prescribed nightly. Titration of the dose was guided
by the effect on ventricular arrhythmia, as determined by
telemetered monitoring as well as the occurrence of side
effects. After the patient had received a stable lorcainide
dose for at least 48 hours, ambulatory electrocardiographic
monitoring and treadmill exercise stress testing were re-
peated to assess drug effect in patients undergoing a non-
invasive evaluation. When an electrophysiologic test was
utilized, it was performed after at least 48 hours of receipt
of a stable lorcainide dose. Routine serum chemistry de-
terminations and a complete blood count were obtained dur-
Invasive
Completed
Lorcainide
Therapy
Effective
Overall
Efficacy
Discharged
On Drug
60 53 16
r-~--I I
56 e 49 15
(t) (t) (t)
~~ ~
28 2828 21 6 9
(N) (Y) (Y) (N) (Y) (N)
\/ I
21 6
(Y) (Y)
-------- ------27(Y)
I
15
I
1e Figure 1. Flow diagram of patients entered into
the study with lorcainide. Of 76 patients, 16 had
invasive electrophysiologic testing while 60 had a
noninvasive evaluation, including ambulatory
electrocardiographic monitoring in all patients and
exercise testing in 53 patients. C:B indicates that
treatment with lorcainide was completed and 8
indicates that side effects necessitated drug discon-
tinuation. (Y) indicates that lorcainide was effec-
tive. (N) means that drug was without effect.
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<±> =Responder
e = Nonresponder
(n) Indicates average cycle length and average
number of cycles
VT = Ventricular Tachycardia
NSVT = Nonsustained Ventricular Tachycardia
* One patient developed a side effect and
did not have a repeat study on drug
Control
Lorcainide
Therapy
16 Patients
/~
Sustained VT NSVT
7 (303ms) 9 (262ms)
/~* /~YCleS
3 3 3 6
(t) e<±> e
(292 ms ) (300ms)
18 cycles
stimuli at two and three times mid-diastolic threshold during
ventricular pacing and sinus rhythm. Up to three extrastimuli
were used in each case, regardless of the number utilized
in the control period. Lorcainide was also considered ef-
fective if sustained ventricular tachycardia, provoked in the
control period, was converted to a nonsustained salvo at a
slower rate and requiring more extrastimuli for initiation.
Plasma concentration determination. Samples of 10
ml of venous blood were separated and the plasma analyzed.
Analysis was performed by the method of Woestenborghs
et al. (14), utilizing gas chromatography. Levels for lor-
cainide and its major metabolite, norlorcainide, were ob-
tained. The protocol for the use of lorcainide was approved
by the Institutional Review Board at both the Harvard School
of Public Health and Brigham and Women's Hospital. In-
formed consent was obtained by one of the investigators.
Data analysis. Statistical analysis was performed using
Student's t test for paired data and the chi-square test. The
criterion of significance was a probability (p) value of less
than 0.05. Results are expressed as mean ± standard
deviation.
Figure 2. Flow diagram of the 16 patients who underwent elec-
trophysiologic study. During control studies, nine patients had
nonsustained ventricular tachycardia (NSYT), while in seven sus-
tained ventricular tachycardia (YT) was provoked. Three patients
who had nonsustained ventricular tachycardia during the control
study and three with sustained ventricular tachycardia responded
to the drug. In nonresponders, there was a decrease in the rate of
the provoked arrhythmia, but this was not significant.
ing the control period and during the administration of the
maximally tolerated dose of drug. Blood for determination
of serum level of lorcainide was obtained 2 hours after a
stable dose.
Lorcainide was considered effective during noninvasive
evaluation when the following criteria were met as judged
by means of ambulatory monitoring and exercise testing: I)
reduction of grade 4A arrhythmia by more than 90%, and
2) total elimination of grade 4B arrhythmia.
The criterion for efficacy when invasive electrophysio-
logic testing was performed was the inability to provoke
any repetitive responses (>2) utilizing up to three extra-
Results
A flow diagram of patients entered into study is shown
in Figure I.
Noninvasive evaluation of lorcainide therapy. Fifty-
six of the 60 patients who underwent noninvasive studies
completed therapy with lorcainide. In four patients, side
effects compelled discontinuation of drug. For the entire
group of 56 patients, lorcainide significantly reduced the
mean number of hours of grade 2 ventricular premature
complexes by 38% (p < 0.05). The number of couplets and
salvos of ventricular tachycardia was also significantly re-
duced (Table 3). In 25 (44.6%) of 56 patients the drug was
judged effective when evaluated by ambulatory electrocar-
diographic monitoring. Eleven patients had total abolition
of repetitive (grade 4A and 4B) arrhythmia, while 14 pa-
tients had a 90% reduction in grade 4A. Three additional
patients, each with more than 250 salvos of ventricular
tachycardia during a 24 hour monitoring period, had only
a single 3 beat episode of ventricular tachycardia while
Table 3. Effect of Lorcainide on Repetitive Arrhythmia Exposed on Electrocardiographic
Monitoring in 56 Patients
Episodes of Ventricular Ectopic Activity per 24 Hours
All patients (n = 56)
Responders (n = 28)
Nonresponders (n = 28)
Couplets
289 ± 201
221 ± 176
404 ± 290
Control
VT
118 ± 279
57 ± 76
189 ± 381
Couplets
130 ± 176:j:
6 ± 10:j:
211 ± 188
Drug
VT
39 ± 105*
ot
66 ± 130*
*p < 0.05; tp < 0.01; :j:p < 0.001. VT = ventricular tachycardia.
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receiving lorcainide and were considered to have clinically
responded to the drug. Thus, 28 patients (50%) were judged
to have responded to lorcainide as evaluated by monitoring.
The number of hours of grade 2 ventricular premature com-
plexes was reduced by 78%, while the number of cou-
plets/day was reduced by 96% (Table 3).
The remaining 28 patients did not respond to lorcainide.
However, the drug significantly reduced the number of hours
per day during which ventricular tachycardia was present
from an average of 9.9 to 3.5 (p < 0.00 I) and the number
of episodes of ventricular tachycardia from 189 to 66 (p <
0.05) (Table 3). Lorcainide reduced the rate of the ventric-
ular tachycardia from an average of 173 to 136 beats/min
(p < 0.05), without altering the duration of each salvo (eight
versus four cycles). The hours of couplets (20 versus 17),
number of couplets (404 versus 211) and hours of grade 2
ventricular premature complexes (22 versus 20) were not
significantly decreased.
Repeat exercise testing. Forty-four of the 53 patients
who had a control exercise test underwent repeat exercise
testing during lorcainide therapy. Side effects necessitating
discontinuation of the drug or persistence of ventricular
tachycardia precluded repeat exercise testing in 9 of the 53
patients. For all 44 patients, lorcainide significantly reduced
the frequency of ventricular premature complexes and cou-
plets per test; 173 versus 75, p < 0.001 and 24 versus 4,
p < 0.05, respectively, although the occurrence of ventric-
ular tachycardia was not altered (12 versus 3, P = not
significant) (Table 4). Lorcainide was deemed effective in
28 of the 44 patients subjected to exercise (63 %). If one
includes the 5 patients with persistent salvos of ventricular
tachycardia who did not undergo repeat exercise testing, the
drug was effective in 28 (57%) of 49 patients. In all re-
sponders, there was a reduction in couplets from a mean of
13 to l/test (p < 0.05), while the frequency of ventricular
premature complexes decreased from a mean of 135 to 8/test
(p < 0.00 1) (Table 4). In nine patients, ventricular arrhyth-
mia was totally abolished. Lorcainide did not alter peak
heart rate and blood pressure, but significantly lengthened
the duration of exercise. In the 16 nonresponders, ventric-
ular premature complex frequency was significantly reduced
from 193 to 117/test (p < 0.01) (Table 4), while couplets
were decreased from 31 to 7/test (p < 0.05); however, the
frequency of salvos of ventricular tachycardia (13 versus
II), the length of each salvo (14 versus II) and the rate of
each salvo (168 versus 152) remained unaltered.
When results of exercise testing and monitoring were
combined, 19 (39%) of 49 patients who underwent both
noninvasive tests had responded to lorcainide (Fig. 3). Ad-
ditionally, two of seven patients who did not have control
exercise testing performed had no arrhythmia during an
exercise test while receiving the drug and responded as
assessed by monitoring. Therefore, of the 56 patients eval-
uated noninvasively, 21 (38%) responded (Fig. I).
Invasive evaluation of lorcainide therapy. Fifteen of
the 16 patients who had control electrophysiologic testing
had a repeat study while receiving lorcainide. In one patient,
frequent episodes of sustained ventricular tachycardia during
drug therapy precluded study. Five of the 15 patients re-
sponded to lorcainide (Fig. 4). In the three patients with
nonsustained ventricular tachycardia as an end point, the
average number of repetitive cycles during the control study
was 10 (range 5 to 15) and in the two patients with sustained
ventricular tachycardia, the rate was 180 and 200 beats/min.
Additionally, one patient in whom sustained ventricular
tachycardia at a rate of 200 beats/min was provoked in the
control period had only a nonsustained paroxysm of ven-
tricular tachycardia at a rate of 98 beats/min induced while
taking lorcainide and the drug was deemed clinically effec-
tive. Thus, 6 (40%) of the 15 patients were considered to
have responded to lorcainide (Fig. 2). In the nine nonre-
sponders, the rate of the provoked arrhythmia was not sig-
nificantly altered (200 versus 196 beats/min).
Of the 71 patients undergoing evaluation with either in-
vasive (15 patients) or noninvasive (56 patients) testing,
lorcainide proved effective in 27 (38%) (Fig. I). The av-
erage daily dose was similar in responders and nonrespond-
ers (259 versus 290 mg, respectively; p = not significant).
Table 4. Exercise Results During Lorcainide Therapy
Ventricular Ectopic Activity per Test
Control Drug
VPCs Couplets VT VPCs Couplets
All patients (n = 44) 173 24 12 75t 4*
Responders (n = 28) 135 13 14 8t 1*
Nonresponders (n = 16) 193 31 13 117* 7*
Duration (min) 6.4 7.2*
Peak heart rate (beats/min) 150 144
Peak systolic BP (mm Hg) 142 143
VT
3
0*
11
*p < 0.05 (versus control); tp < 0.001 (compared with control); VPCs = ventricular premature complexes;
VT = ventricular tachycardia.
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Figure 3. Tracings from a responder during noninvasive evalu-
ation of lorcainide. During control studies, frequent ventricular
couplets (grade 4A) and salvos of ventricular tachycardia (grade
48) were present. After 72 hours of lorcainide therapy, repetitive
arrhythmia was abolished. HR = heart rate (beats/min).
Blood levels of lorcainide and norlorcainide were 375 ±
246 and 268 ± 235 ng/mI, respectively, in responders and
305 ± 185 and 274 ± 178 ng/ml, respectively, in non-
responders, There was no significant difference in these
levels. Drug effectiveness appeared unrelated to the type
and severity of the heart disease. Lorcainide was more likely
to suppress advanced grades of arrhythmia in those having
lesser frequencies of these types of ectopic complexes. The
average number of hours of grade 4B and 4A arrhythmia
during the control phase was 13.1 and 20.1, respectively,
in nonresponders versus 7.1 and 14.7, respectively, in re-
sponders (p < 0,01).
Side effects. These occurred in 42 patients (55.3%) (Ta-
ble 5), The most frequent complaint was insomnia, reported
by 29 patients. The sleep disturbance occurred despite con-
comitant therapy with flurazepam or oxazepam. Eight pa-
tients had nausea and vomiting; dizziness, complete heart
block and rash each occurred in one patient. In seven pa-
tients (9.2%), arrhythmia was worsened (Fig. 5), Four had
ventricular fibrillation for the first time and two developed
a sustained episode of ventricular tachycardia requiring car-
dioversion, although they had only nonsustained salvos dur-
ing the control period, One patient who required electro-
physiologic testing developed spontaneous episodes of
sustained tachycardia while receiving lorcainide, Serum lev-
els of lorcainide and norlorcainide in patients with side
effects were 317 ± 238 and 239 ± 208 ng/ml, respectively.
These were not significantly different from levels in those
without side effects (352 ± 202 and 293 ± 203 ng/ml,
respectively), No changes in serum chemistry determina-
tions or other laboratory tests occurred.
Figure 4. Tracings from a responder to lorcainide with electro-
physiologic evaluation, In a control study, one extrastimulus (Sf)
provoked sustained ventricular tachycardia (VT). During lorcain-
ide therapy, no arrhythmia is provoked when three extrastimuli
(Sf, S2, S3) are added.
T,r.-:r.="..,,;r.Cir°:!,NjTROl r-r-r-,.....,..,,.....,,-,-,--r," " .~. Wi IIi; ';.~ '!/' 'E' :~ ". ;'L ;,,: : ' ...
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Table 5. Side Effects in 42 (55.3%) of 76 Patients
Figure 5. Example of aggravation of arrhythmia during electro-
physiologic study. In the control study. three extrastimuli (S I. S!.
S,) added during a paced (P) rhythm were necessary to provoke
nonsustained ventricular tachycardia (SYT). During lorcainide
therapy, a single premature extrastimulus (Sil provokes sustained
ventricular tachycardia (vt). rate = heart rate (beats/min).
Long-term results. Lorcainide was considered to be the
most effective drug among several agents tested. It was well
tolerated during the hospital stay in 15 patients and was
maintained on discharge. Insomnia of increasing severity
compelled discontinuation of lorcainide in four patients after
I to 2 months. Three patients died within 2 months of
discharge. In two, death was from congestive heart failure
unrelated to lorcainide, while one patient died suddenly.
The remaining eight patients have continued on lorcainide
therapy for an average of 23 months (range 9 to 34), free
of arrhythmia or side effects.
fibrillation threshold (16). In clinical electrophysiologic studies
(17-19), sinus node recovery time, particularly in those with
sinus node dysfunction, may be prolonged. Atrioventricular
conduction time is lengthened while the effect on the re-
fractory period is variable. Ventricular conduction time and
refractory period are prolonged. Changes on the electro-
cardiogram are uncommonly observed, but when present,
they reflect these electrophysiologic effects (20). The most
frequent change, widening of the QRS complex, is dose-
related and correlates with the plasma drug level (21).
With intravenous lorcainide. hemodynamic changes are
minimal and of brief duration. Meinertz et al. (21) observed
no statistically significant changes in systemic vascular re-
sistance or cardiac output, although there were slight re-
ductions in left ventricular inotropy (dP/dT) and circum-
ferential fiber shortening. There were no consistent changes
in heart rate or blood pressure. Hemodynamic effects with
oral drug therapy have not been adequately examined. There
have been no reports of lorcainide-induced congestive heart
failure.
Clinical results of lorcainide for suppressing ventric-
ular arrhythmia. In our study, lorcainide proved effective
in 27 (38%) of 71 patients, a response not dissimilar to the
experience with other antiarrhythmic agents in a similar
group of patients (22,23). A number of studies (7,17,24)
reported a higher success rate. However, there are differ-
ences in methods of evaluation, criteria for judging efficacy
and the subset of patients studied. Previous reports have
limited evaluation with ambulatory electrocardiographic
monitoring, and efficacy was exclusively related to a de-
crease in frequency of ventricular premature complexes. Our
criteria included total abolition of ventricular tachycardia
and more than 90% reduction of couplets. Although a change
in ventricular premature complex frequency was not con-
sidered a necessary criterion, those responding had an av-
erage reduction of 78% in grade 2 ventricular premature
complexes. We assessed efficacy by means of monitoring
and exercise testing and included patients who had had out
of hospital ventricular tachycardia or fibrillation that was
refractory to conventional drugs. In a majority of previous
studies, lorcainide was evaluated in patients with frequent
ventricular ectopic complexes who had not experienced se-
rious or sustained tachyarrhythmias. An exception is the
report by Cocco and Strazzi (25), who studied seven patients
with recurrent ventricular tachycardia and ventricular fi-
brillation refractory to drugs. Lorcainide at a dose of I()()
mg three times daily totally suppressed arrhythmia in six of
their patients. Somani (26) utilized intravenous lorcainide
at a total dose of 125 to 200 mg in 10 patients with ven-
tricular arrhythmia,S of whom had a history of ventricular
tachycardia. Arrhythmia was reduced in a dose-dependent
manner in all 10 patients and was totally abolished in 4.
Although in our study only 38% of patients responded
to lorcainide, the frequency of ventricular arrhythmia was
29
8
I
I
I
7
No. of
Patients
Discussion
Life-threatening ventricular arrhythmias occurring in the
absence of acute provoking factors require long-term anti-
arrhythmic therapy (15). The diversity of individual re-
sponse and tolerance requires availability of a multiplicity
of drugs. Lorcainide is one new agent now under study. In
isolated canine tissue, lorcainide has been found to resemble
membrane-active drugs in reducing the upstroke velocity of
phase 0, decreasing maximal amplitude of the action po-
tential, slowing conduction velocity and prolonging action
potential duration (16). It strikingly increases the ventricular
Insomnia
Gastrointestinal
Rash
Dizziness
Complete heart block
Aggravation of arrhythmia
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reduced in those who did not meet our strict criteria for
drug efficacy. The number of salvos of ventricular tachy-
cardia and couplets was significantly diminished. Addition-
ally, there was a significant decrease in the rate of the
ventricular tachycardia from 179 to 136 beats/min (p <
0.05). This reduction in the rate of tachyarrhythmia may
allow the patient to tolerate the arrhythmia without sub-
stantial hemodynamic impairment.
Untoward effects from lorcainide. Side effects were
encountered in 42 patients. The most common complaints
were insomnia and nausea. Significant toxicity necessitated
discontinuation of lorcainide early during the course of ther-
apy in five patients. Aggravation of arrhythmia was ob-
served in seven patients (9.2%), a finding not dissimilar to
our experience with other conventional and investigational
antiarrhythmic agents (27). Lorcainide has not been reported
to cause major changes in hemodynamic state, and we did
not observe any exacerbation of congestive heart failure in
the 45 patients who had a history of left ventricular dys-
function. This is in contrast to our experience with some of
the other membrane-active drugs in a similar group of pa-
tients (22,28).
The frequency of side effects with lorcainide is similar
to that reported by others (8,29). It has been reported (8)
that insomnia may be prevented by pretreatment with ben-
zodiazapine drugs during initial therapy with lorcainide.
Moreover, the insomnia may resolve after several weeks of
continued drug use (8). This has not been our experience.
Insomnia was a frequent side effect despite pretreatment
with soporific agents. Drug therapy was discontinued in four
patients after more than I month of continued therapy be-
cause of persistent sleep disturbances.
Conclusion. We conclude that in some patients who
have been refractory to or intolerant of conventional an-
tiarrhythmic agents, lorcainide may have a role in the treat-
ment of life-threatening ventricular arrhythmias. When ar-
rhythmias are of high density and are reproducible, efficacy
is readily determined by both electrocardiographic moni-
toring and exercise testing. In those without adequate ec-
topic activity, electrophysiologic study is mandated. Lor-
cainide induces frequent side effects, especially insomnia,
and these may preclude its long-term use. When a systematic
approach to drug therapy, as applied in this study to eval-
uation of lorcainide, is employed, an effective agent can be
selected for the individual patient and potential side effects
can be identified. If lorcainide is effective and well tolerated
during short-term evaluation, long-term therapy is usually
successful.
We thank Helene Glaser, RN, Ellen Matathia, RN and Margo Mitchell,
RN for their valuable assistance and Claudia Kenney and Marian Cordaro
for their secretarial skills.
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